{"id":39269,"date":"2026-02-02T10:50:09","date_gmt":"2026-02-02T10:50:09","guid":{"rendered":"https:\/\/organonpro.com\/es-es\/?post_type=news&#038;p=39269"},"modified":"2026-06-17T07:48:44","modified_gmt":"2026-06-17T07:48:44","slug":"tratamientos-biologicos-y-episodios-cardiovasculares-adversos-graves","status":"publish","type":"news","link":"https:\/\/organonpro.com\/es-es\/news\/tratamientos-biologicos-y-episodios-cardiovasculares-adversos-graves\/","title":{"rendered":"Tratamientos biol\u00f3gicos\u00a0y\u00a0episodios cardiovasculares adversos graves: revisi\u00f3n sistem\u00e1tica y\u00a0metan\u00e1lisis\u00a0"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><em>Mangkorntongsakul\u00a0V, Joseph JS, Pham JP, Smith SD, Chow CK, Smith AD.\u00a0Biologic Therapies\u00a0and Major Cardiovascular Events in Psoriasis: Updated Systematic Review and Meta-analysis.\u00a0Dermatol\u00a0Ther\u00a0(Heidelb). 2025 Dec;15(12):3547-3560.\u00a0\u00a0<\/em><\/p>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-black-color has-text-color has-link-color wp-elements-fe8b53361a2f5864081ce477bae2917d\" style=\"font-size:27px;font-style:normal;font-weight:700\">Puntos clave:<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Este estudio evalu\u00f3 la incidencia de episodios cardiovasculares adversos graves\u00a0(ECAG)\u00a0en pacientes con psoriasis de moderada a grave que recibieron tratamiento biol\u00f3gico<em>.<\/em>\u00a0<\/li>\n\n\n\n<li>No se observ\u00f3 una asociaci\u00f3n estad\u00edsticamente significativa entre la incidencia de ECAG y los tratamientos biol\u00f3gicos\u00a0en todos los ensayos que comparaban los tratamientos biol\u00f3gicos\u00a0con placebo.\u00a0<\/li>\n\n\n\n<li>Tampoco\u00a0se encontraron diferencias significativas en la incidencia de ECAG\u00a0entre clases\u00a0espec\u00edficas\u00a0de\u00a0f\u00e1rmacos\u00a0biol\u00f3gicos.\u00a0<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">La psoriasis es un trastorno inflamatorio cr\u00f3nico, recidivante e inmunitario que afecta al\u00a02\u202f%-3\u202f% de la poblaci\u00f3n mundial.\u00a0Se ha visto\u00a0que la psoriasis no es\u00a0un trastorno puramente cut\u00e1neo, sino un s\u00edndrome inflamatorio sist\u00e9mico mediado por\u00a0linfocitos\u00a0T\u00a0que presenta\u00a0afectaci\u00f3n cut\u00e1nea.\u00a0<\/p>\n\n\n\n<p class=\"has-text-align-left borde-citas has-text-color has-background has-link-color wp-elements-2e2b97575cb439db6d01062c44d7afa4 wp-block-paragraph\" style=\"color:#1b4298;background-color:#fff8cc;font-size:18px;font-style:normal;font-weight:600\">Se ha encontrado\u00a0una fuerte asociaci\u00f3n\u00a0entre la psoriasis y los episodios\u00a0cardiovasculares.\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Por otra parte, recientemente han aparecido&nbsp;f\u00e1rmacos&nbsp;biol\u00f3gicos&nbsp;selectivos&nbsp;muy&nbsp;efectivos. Aunque&nbsp;sus&nbsp;beneficios cut\u00e1neos est\u00e1n bien establecidos,&nbsp;su efecto sobre los&nbsp;episodios cardiovasculares adversos graves&nbsp;(ECAG) sigue sin estar claro.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Esta&nbsp;revisi\u00f3n sistem\u00e1tica&nbsp;con&nbsp;metan\u00e1lisis&nbsp;evalu\u00f3&nbsp;la incidencia de&nbsp;ECAG&nbsp;con los tratamientos biol\u00f3gicos disponibles en pacientes con psoriasis de moderada a grave.&nbsp;<\/p>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-black-color has-text-color has-link-color wp-elements-801f518c612b8d8c29b44410f51b8caf\" style=\"font-size:27px;font-style:normal;font-weight:700\">Metodolog\u00eda\u00a0<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Se hizo una b\u00fasqueda el 10 de mayo de 2022 en las bases de datos&nbsp;Ovid&nbsp;Medline, PubMed, Registro Central Cochrane de Ensayos Controlados (CCTR), Base de Datos Cochrane de Revisiones Sistem\u00e1ticas (CDSR) y EMBASE, as\u00ed como en el registro ClinicalTrials.gov y&nbsp;la&nbsp;Plataforma de Registros&nbsp;Internacional de Ensayos Cl\u00ednicos de la&nbsp;OMS.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">El&nbsp;criterio de valoraci\u00f3n principal&nbsp;fue la incidencia de&nbsp;ECAG. La definici\u00f3n de&nbsp;ECAG&nbsp;inclu\u00eda&nbsp;el&nbsp;infarto de miocardio no mortal,&nbsp;los episodios&nbsp;cerebrovasculares no mortales (accidentes cerebrovasculares isqu\u00e9micos y hemorr\u00e1gicos) y&nbsp;la&nbsp;muerte&nbsp;por causas&nbsp;cardiovasculares.&nbsp;<\/p>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-black-color has-text-color has-link-color wp-elements-0c3411b7a9714e463f6a0f6d8f1290c2\" style=\"font-size:27px;font-style:normal;font-weight:700\">Resultados\u00a0<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Se seleccionaron\u00a036 ensayos controlados y aleatorizados\u00a0(ECA)\u00a0con 24\u202f083 pacientes, de los cuales 19\u202f695 recibieron tratamientos biol\u00f3gicos y 5288 recibieron placebo.\u00a0En\u00a0los ensayos que comparaban tratamientos biol\u00f3gicos con placebo,\u00a013\u00a0utilizaron\u00a0inhibidores del\u00a0TNF-\u03b1,\u00a017 inhibidores de\u00a0la\u00a0IL-17,\u00a07 inhibidores de\u00a0las\u00a0IL-12\/23 y\u00a010 inhibidores de\u00a0la\u00a0IL-23. En otros estudios se compararon tratamientos biol\u00f3gicos entre s\u00ed.\u00a0<\/p>\n\n\n\n<p class=\"has-text-align-left borde-citas has-text-color has-background has-link-color wp-elements-99ba706e991e59de044e20c069c06a2b wp-block-paragraph\" style=\"color:#1b4298;background-color:#fff8cc;font-size:18px;font-style:normal;font-weight:600\">Seg\u00fan todos los ECA que comparaban los tratamientos biol\u00f3gicos\u00a0con placebo, no se observ\u00f3 una asociaci\u00f3n estad\u00edsticamente significativa entre la incidencia de\u00a0ECAG\u00a0y los tratamientos biol\u00f3gicos (odds\u00a0ratio\u00a0de Peto[POR]: 1,26;\u00a0p\u00a0= 0,6) en pacientes adultos con psoriasis de moderada a grave.\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">No se encontraron\u00a0diferencias estad\u00edsticamente significativas en la incidencia de\u00a0ECAG\u00a0para los inhibidores del\u00a0TNF-\u03b1 (adalimumab,\u00a0infliximab\u00a0y\u00a0etanercept) (POR 1,13,\u00a0<em>p<\/em>\u00a0= 0,86),\u00a0los\u00a0inhibidores de\u00a0la\u00a0IL-17 (secukinumab,\u00a0ixekizumab,\u00a0brodalumab\u00a0y\u00a0bimekizumab) (POR 0,60,\u00a0<em>p<\/em>\u00a0= 0,45),\u00a0los\u00a0inhibidores de\u00a0las\u00a0IL 12\/23 (usetekinumab) (POR 4,56,\u00a0<em>p<\/em>\u00a0= 0,14) y los\u00a0inhibidores de\u00a0la\u00a0IL-23 (guselkumab,\u00a0risankizumab\u00a0y\u00a0tildrakizumab) (OR 1,32,\u00a0<em>p<\/em>\u00a0= 0,79).\u00a0<\/p>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-black-color has-text-color has-link-color wp-elements-ad4eaa7bd75c4f188669fff46928d6f9\" style=\"font-size:27px;font-style:normal;font-weight:700\">Discusi\u00f3n\u00a0<\/h2>\n\n\n\n<p class=\"has-text-align-left borde-citas has-text-color has-background has-link-color wp-elements-fa6a26bbc176f07de421e947a8827585 wp-block-paragraph\" style=\"color:#1b4298;background-color:#fff8cc;font-size:18px;font-style:normal;font-weight:600\">Los resultados de esta revisi\u00f3n sistem\u00e1tica y\u00a0metan\u00e1lisis\u00a0confirman los datos\u00a0previos, que indican que los tratamientos biol\u00f3gicos no modifican significativamente el riesgo de\u00a0ECAG\u00a0en\u00a0adultos con psoriasis moderada ograve.\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">No se encontraron diferencias significativas en la incidencia de&nbsp;ECAG&nbsp;entre pacientes con&nbsp;psoriasis que recibieron tratamiento biol\u00f3gico&nbsp;y aquellos que recibieron placebo, ni entre clases&nbsp;espec\u00edficas&nbsp;de&nbsp;f\u00e1rmacos&nbsp;biol\u00f3gicos. No obstante, los datos recientes&nbsp;de estudios&nbsp;mecan\u00edsticos&nbsp;y de imagen sugieren&nbsp;que los&nbsp;biol\u00f3gicos podr\u00edan tener efectos favorables sobre la enfermedad cardiovascular&nbsp;subcl\u00ednica.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Una limitaci\u00f3n importante de la presente revisi\u00f3n es que la mayor\u00eda de las fases controladas\u00a0de los ECA se dise\u00f1aron para\u00a0una\u00a0eficacia a corto plazo, no para la seguridad cardiovascular a largo plazo,\u00a0y\u00a0suelen\u00a0tener\u00a0un seguimiento de\u00a0\u22641 a\u00f1o. Dado que los\u00a0ECAG\u00a0pueden manifestarse a\u00f1os despu\u00e9s del inicio del tratamiento, estos ensayos previos podr\u00edan subestimar la incidencia real.\u00a0<\/p>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-black-color has-text-color has-link-color wp-elements-633cbd23b7ae6b2e3d5acbf033c45c05\" style=\"font-size:27px;font-style:normal;font-weight:700\">Conclusiones\u00a0<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Hay datos recientes\u00a0que\u00a0indican\u00a0que los tratamientos biol\u00f3gicos pueden modular la inflamaci\u00f3n sist\u00e9mica en general y la carga de\u00a0la\u00a0placa coronaria en particular, lo que, te\u00f3ricamente, podr\u00eda traducirse en una reducci\u00f3n de la incidencia de\u00a0ECAG. Sin embargo, en este estudio,\u00a0no se encontr\u00f3 una reducci\u00f3n de la incidencia de ECAG con el\u00a0tratamiento biol\u00f3gico.\u00a0Por otro lado, tampoco parece que los f\u00e1rmacos\u00a0biol\u00f3gicos actuales aumenten\u00a0la incidencia de\u00a0ECAG\u00a0en\u00a0lospacientes con psoriasis grave.\u00a0<\/p>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00bfQuieres ampliar la informaci\u00f3n?<\/strong> Consulta el art\u00edculo original completo <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41145722\/\">Biologic Therapies and Major Cardiovascular Events in Psoriasis: Updated Systematic Review and Meta-analysis<\/a><\/p>\n\n\n\n<style>\n.borde-citas {\nborder: solid;\nborder-color: #FEDB00;\nborder-width: 1px 1px 1px 16px;\nborder-radius: 0.8rem;\n}\n<\/style>\n","protected":false},"excerpt":{"rendered":"<p>Mangkorntongsakul\u00a0V, Joseph JS, Pham JP, Smith SD, Chow CK, Smith AD.\u00a0Biologic Therapies\u00a0and Major Cardiovascular Events in Psoriasis: Updated Systematic Review and Meta-analysis.\u00a0Dermatol\u00a0Ther\u00a0(Heidelb). 2025 Dec;15(12):3547-3560.\u00a0\u00a0 Puntos clave: La psoriasis es un trastorno inflamatorio cr\u00f3nico, recidivante e inmunitario que afecta al\u00a02\u202f%-3\u202f% de la poblaci\u00f3n mundial.\u00a0Se ha visto\u00a0que la psoriasis no es\u00a0un trastorno puramente cut\u00e1neo, sino un s\u00edndrome [&hellip;]<\/p>\n","protected":false},"author":120,"featured_media":39424,"parent":0,"menu_order":0,"template":"","meta":{"_acf_changed":true},"tags":[],"news_categories":[214,213,234],"class_list":["post-39269","news","type-news","status-publish","has-post-thumbnail","hentry","news_categories-cardiologia","news_categories-dermatologia","news_categories-medicina-interna"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.7 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Tratamientos biol\u00f3gicos\u00a0y\u00a0episodios cardiovasculares adversos graves: revisi\u00f3n sistem\u00e1tica y\u00a0metan\u00e1lisis\u00a0 - Organon Pro - Espa\u00f1a<\/title>\n<meta name=\"description\" content=\"Actual\u00edzate en unos minutos sobre los tratamientos biol\u00f3gicos y episodios cardiovasculares adversos graves\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/organonpro.com\/es-es\/news\/tratamientos-biologicos-y-episodios-cardiovasculares-adversos-graves\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tratamientos biol\u00f3gicos\u00a0y\u00a0episodios cardiovasculares adversos graves: revisi\u00f3n sistem\u00e1tica y\u00a0metan\u00e1lisis\u00a0\" \/>\n<meta property=\"og:description\" content=\"Actual\u00edzate en unos minutos sobre los tratamientos biol\u00f3gicos y episodios cardiovasculares adversos graves\" \/>\n<meta property=\"og:url\" content=\"https:\/\/organonpro.com\/es-es\/news\/tratamientos-biologicos-y-episodios-cardiovasculares-adversos-graves\/\" \/>\n<meta property=\"og:site_name\" content=\"Organon Pro - Espa\u00f1a\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/OrganonandCo\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-17T07:48:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/organonpro.com\/es-es\/wp-content\/uploads\/sites\/11\/2026\/02\/resumen-cardiovasculares-adversos.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"676\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@OrganonLLC\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/organonpro.com\\\/es-es\\\/news\\\/tratamientos-biologicos-y-episodios-cardiovasculares-adversos-graves\\\/\",\"url\":\"https:\\\/\\\/organonpro.com\\\/es-es\\\/news\\\/tratamientos-biologicos-y-episodios-cardiovasculares-adversos-graves\\\/\",\"name\":\"Tratamientos biol\u00f3gicos\u00a0y\u00a0episodios cardiovasculares adversos graves: revisi\u00f3n sistem\u00e1tica y\u00a0metan\u00e1lisis\u00a0 - Organon Pro - Espa\u00f1a\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/organonpro.com\\\/es-es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/organonpro.com\\\/es-es\\\/news\\\/tratamientos-biologicos-y-episodios-cardiovasculares-adversos-graves\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/organonpro.com\\\/es-es\\\/news\\\/tratamientos-biologicos-y-episodios-cardiovasculares-adversos-graves\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/organonpro.com\\\/es-es\\\/wp-content\\\/uploads\\\/sites\\\/11\\\/2026\\\/02\\\/resumen-cardiovasculares-adversos.jpg\",\"datePublished\":\"2026-02-02T10:50:09+00:00\",\"dateModified\":\"2026-06-17T07:48:44+00:00\",\"description\":\"Actual\u00edzate en unos minutos sobre los tratamientos biol\u00f3gicos y episodios cardiovasculares adversos graves\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/organonpro.com\\\/es-es\\\/news\\\/tratamientos-biologicos-y-episodios-cardiovasculares-adversos-graves\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/organonpro.com\\\/es-es\\\/news\\\/tratamientos-biologicos-y-episodios-cardiovasculares-adversos-graves\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/organonpro.com\\\/es-es\\\/news\\\/tratamientos-biologicos-y-episodios-cardiovasculares-adversos-graves\\\/#primaryimage\",\"url\":\"https:\\\/\\\/organonpro.com\\\/es-es\\\/wp-content\\\/uploads\\\/sites\\\/11\\\/2026\\\/02\\\/resumen-cardiovasculares-adversos.jpg\",\"contentUrl\":\"https:\\\/\\\/organonpro.com\\\/es-es\\\/wp-content\\\/uploads\\\/sites\\\/11\\\/2026\\\/02\\\/resumen-cardiovasculares-adversos.jpg\",\"width\":1200,\"height\":676,\"caption\":\"Tratamientos biol\u00f3gicos y episodios cardiovasculares adversos graves: revisi\u00f3n sistem\u00e1tica y metan\u00e1lisis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/organonpro.com\\\/es-es\\\/news\\\/tratamientos-biologicos-y-episodios-cardiovasculares-adversos-graves\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/organonpro.com\\\/es-es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/organonpro.com\\\/es-es\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Tratamientos biol\u00f3gicos\u00a0y\u00a0episodios cardiovasculares adversos graves: revisi\u00f3n sistem\u00e1tica y\u00a0metan\u00e1lisis\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/organonpro.com\\\/es-es\\\/#website\",\"url\":\"https:\\\/\\\/organonpro.com\\\/es-es\\\/\",\"name\":\"Organon Pro - Espa\u00f1a\",\"description\":\"Organon Pro - Espa\u00f1a\",\"publisher\":{\"@id\":\"https:\\\/\\\/organonpro.com\\\/es-es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/organonpro.com\\\/es-es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/organonpro.com\\\/es-es\\\/#organization\",\"name\":\"Organon Pro - Espa\u00f1a\",\"url\":\"https:\\\/\\\/organonpro.com\\\/es-es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/organonpro.com\\\/es-es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/organonpro.com\\\/es-es\\\/wp-content\\\/uploads\\\/sites\\\/11\\\/2023\\\/08\\\/organon-pro-1.webp\",\"contentUrl\":\"https:\\\/\\\/organonpro.com\\\/es-es\\\/wp-content\\\/uploads\\\/sites\\\/11\\\/2023\\\/08\\\/organon-pro-1.webp\",\"width\":2269,\"height\":243,\"caption\":\"Organon Pro - Espa\u00f1a\"},\"image\":{\"@id\":\"https:\\\/\\\/organonpro.com\\\/es-es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/OrganonandCo\",\"https:\\\/\\\/x.com\\\/OrganonLLC\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Tratamientos biol\u00f3gicos\u00a0y\u00a0episodios cardiovasculares adversos graves: revisi\u00f3n sistem\u00e1tica y\u00a0metan\u00e1lisis\u00a0 - Organon Pro - Espa\u00f1a","description":"Actual\u00edzate en unos minutos sobre los tratamientos biol\u00f3gicos y episodios cardiovasculares adversos graves","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/organonpro.com\/es-es\/news\/tratamientos-biologicos-y-episodios-cardiovasculares-adversos-graves\/","og_locale":"en_US","og_type":"article","og_title":"Tratamientos biol\u00f3gicos\u00a0y\u00a0episodios cardiovasculares adversos graves: revisi\u00f3n sistem\u00e1tica y\u00a0metan\u00e1lisis\u00a0","og_description":"Actual\u00edzate en unos minutos sobre los tratamientos biol\u00f3gicos y episodios cardiovasculares adversos graves","og_url":"https:\/\/organonpro.com\/es-es\/news\/tratamientos-biologicos-y-episodios-cardiovasculares-adversos-graves\/","og_site_name":"Organon Pro - Espa\u00f1a","article_publisher":"https:\/\/www.facebook.com\/OrganonandCo","article_modified_time":"2026-06-17T07:48:44+00:00","og_image":[{"width":1200,"height":676,"url":"https:\/\/organonpro.com\/es-es\/wp-content\/uploads\/sites\/11\/2026\/02\/resumen-cardiovasculares-adversos.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@OrganonLLC","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/organonpro.com\/es-es\/news\/tratamientos-biologicos-y-episodios-cardiovasculares-adversos-graves\/","url":"https:\/\/organonpro.com\/es-es\/news\/tratamientos-biologicos-y-episodios-cardiovasculares-adversos-graves\/","name":"Tratamientos biol\u00f3gicos\u00a0y\u00a0episodios cardiovasculares adversos graves: revisi\u00f3n sistem\u00e1tica y\u00a0metan\u00e1lisis\u00a0 - Organon Pro - Espa\u00f1a","isPartOf":{"@id":"https:\/\/organonpro.com\/es-es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/organonpro.com\/es-es\/news\/tratamientos-biologicos-y-episodios-cardiovasculares-adversos-graves\/#primaryimage"},"image":{"@id":"https:\/\/organonpro.com\/es-es\/news\/tratamientos-biologicos-y-episodios-cardiovasculares-adversos-graves\/#primaryimage"},"thumbnailUrl":"https:\/\/organonpro.com\/es-es\/wp-content\/uploads\/sites\/11\/2026\/02\/resumen-cardiovasculares-adversos.jpg","datePublished":"2026-02-02T10:50:09+00:00","dateModified":"2026-06-17T07:48:44+00:00","description":"Actual\u00edzate en unos minutos sobre los tratamientos biol\u00f3gicos y episodios cardiovasculares adversos graves","breadcrumb":{"@id":"https:\/\/organonpro.com\/es-es\/news\/tratamientos-biologicos-y-episodios-cardiovasculares-adversos-graves\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/organonpro.com\/es-es\/news\/tratamientos-biologicos-y-episodios-cardiovasculares-adversos-graves\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/organonpro.com\/es-es\/news\/tratamientos-biologicos-y-episodios-cardiovasculares-adversos-graves\/#primaryimage","url":"https:\/\/organonpro.com\/es-es\/wp-content\/uploads\/sites\/11\/2026\/02\/resumen-cardiovasculares-adversos.jpg","contentUrl":"https:\/\/organonpro.com\/es-es\/wp-content\/uploads\/sites\/11\/2026\/02\/resumen-cardiovasculares-adversos.jpg","width":1200,"height":676,"caption":"Tratamientos biol\u00f3gicos y episodios cardiovasculares adversos graves: revisi\u00f3n sistem\u00e1tica y metan\u00e1lisis"},{"@type":"BreadcrumbList","@id":"https:\/\/organonpro.com\/es-es\/news\/tratamientos-biologicos-y-episodios-cardiovasculares-adversos-graves\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/organonpro.com\/es-es\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/organonpro.com\/es-es\/news\/"},{"@type":"ListItem","position":3,"name":"Tratamientos biol\u00f3gicos\u00a0y\u00a0episodios cardiovasculares adversos graves: revisi\u00f3n sistem\u00e1tica y\u00a0metan\u00e1lisis\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/organonpro.com\/es-es\/#website","url":"https:\/\/organonpro.com\/es-es\/","name":"Organon Pro - Espa\u00f1a","description":"Organon Pro - Espa\u00f1a","publisher":{"@id":"https:\/\/organonpro.com\/es-es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/organonpro.com\/es-es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/organonpro.com\/es-es\/#organization","name":"Organon Pro - Espa\u00f1a","url":"https:\/\/organonpro.com\/es-es\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/organonpro.com\/es-es\/#\/schema\/logo\/image\/","url":"https:\/\/organonpro.com\/es-es\/wp-content\/uploads\/sites\/11\/2023\/08\/organon-pro-1.webp","contentUrl":"https:\/\/organonpro.com\/es-es\/wp-content\/uploads\/sites\/11\/2023\/08\/organon-pro-1.webp","width":2269,"height":243,"caption":"Organon Pro - Espa\u00f1a"},"image":{"@id":"https:\/\/organonpro.com\/es-es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/OrganonandCo","https:\/\/x.com\/OrganonLLC"]}]}},"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/organonpro.com\/es-es\/wp-json\/wp\/v2\/news\/39269","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/organonpro.com\/es-es\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/organonpro.com\/es-es\/wp-json\/wp\/v2\/types\/news"}],"author":[{"embeddable":true,"href":"https:\/\/organonpro.com\/es-es\/wp-json\/wp\/v2\/users\/120"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/organonpro.com\/es-es\/wp-json\/wp\/v2\/media\/39424"}],"wp:attachment":[{"href":"https:\/\/organonpro.com\/es-es\/wp-json\/wp\/v2\/media?parent=39269"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/organonpro.com\/es-es\/wp-json\/wp\/v2\/tags?post=39269"},{"taxonomy":"news_categories","embeddable":true,"href":"https:\/\/organonpro.com\/es-es\/wp-json\/wp\/v2\/news_categories?post=39269"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}